Company profile
Hansa Biopharma Limited is a UK company with status active founded in 2013 based in South East England.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzODU2OTAxNGFkaXF6a2N4 | Paper/PDF filed
Published 14 Oct 2024 05:42
Company registered at Companies House
Immago is developing innovations in the field of therapeutic antibodies arising from work in the Glycobiology Institute of the University of Oxford. With our technology we seek to enable a new generation of cancer therapies by enhancing the efficacy of therapeutic monoclonal antibodies (mAbs). Working with partners, we aim to develop better anti-cancer therapies, by improving the efficacy of existing and abandoned mAbs, and developing novel mAbs taking advantage of our unique knowledge of the field of therapeutic glycoproteins.
Immago Biosystems was acquired by Hansa Medical (now Hansa Biopharma). The technology is now branded as Enzyme-based antibody Enhancement and is described on their website as below. https://hansabiopharma.com/innovation-focus/our-technology/ Enzyme-based antibody Enhancement EnzE (Enzyme-based antibody Enhancement) is a pre-clinical research and development program under which the combined use of approved antibody-based cancer treatments with IgG-modulating enzymes is explored. High levels of plasma IgG have been associated with limiting the efficacy of therapeutic antibodies, as plasma IgG can saturate the Fc-receptors of the patient's immune cells and thereby prevent them from effectively killing the cancer cells.
